Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

we're building Novo Nordisk's ability to serve millions more people living with serious chronic diseases in the future." The new facility expects to obtain LEED Gold certification by utilizing ...